BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

930 related articles for article (PubMed ID: 33541109)

  • 21. Effectiveness and safety among direct oral anticoagulants in nonvalvular atrial fibrillation: A multi-database cohort study with meta-analysis.
    Durand M; Schnitzer ME; Pang M; Carney G; Eltonsy S; Filion KB; Fisher A; Jun M; Kuo IF; Matteau A; Paterson JM; Quail J; Renoux C;
    Br J Clin Pharmacol; 2021 Jun; 87(6):2589-2601. PubMed ID: 33242339
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety and efficacy of apixaban, dabigatran and rivaroxaban in obese and morbidly obese patients with heart failure and atrial fibrillation: A real-world analysis.
    Chugh Y; Gupta K; Krishna HB; Ayala RQ; Zepeda I; Grushko M; Faillace RT
    Pacing Clin Electrophysiol; 2023 Jan; 46(1):50-58. PubMed ID: 36419246
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Oral anticoagulants for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis, and cost effectiveness analysis.
    López-López JA; Sterne JAC; Thom HHZ; Higgins JPT; Hingorani AD; Okoli GN; Davies PA; Bodalia PN; Bryden PA; Welton NJ; Hollingworth W; Caldwell DM; Savović J; Dias S; Salisbury C; Eaton D; Stephens-Boal A; Sofat R
    BMJ; 2017 Nov; 359():j5058. PubMed ID: 29183961
    [No Abstract]   [Full Text] [Related]  

  • 24. Prescription Patterns and Outcomes of Patients With Atrial Fibrillation Treated With Direct Oral Anticoagulants and Warfarin: A Real-World Analysis.
    Kattoor AJ; Pothineni NV; Goel A; Syed M; Syed S; Paydak H; Mehta JL
    J Cardiovasc Pharmacol Ther; 2019 Sep; 24(5):428-434. PubMed ID: 31035795
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparative clinical outcomes between direct oral anticoagulants and warfarin among elderly patients with non-valvular atrial fibrillation in the CMS medicare population.
    Amin A; Keshishian A; Dina O; Dhamane A; Nadkarni A; Carda E; Russ C; Rosenblatt L; Mardekian J; Yuce H; Baker CL
    J Thromb Thrombolysis; 2019 Aug; 48(2):240-249. PubMed ID: 30924051
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-Term Population-Based Cerebral Ischemic Event and Cognitive Outcomes of Direct Oral Anticoagulants Compared With Warfarin Among Long-term Anticoagulated Patients for Atrial Fibrillation.
    Jacobs V; May HT; Bair TL; Crandall BG; Cutler MJ; Day JD; Mallender C; Osborn JS; Stevens SM; Weiss JP; Woller SC; Bunch TJ
    Am J Cardiol; 2016 Jul; 118(2):210-4. PubMed ID: 27236255
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparative Effectiveness and Safety of Direct Oral Anticoagulants Versus Warfarin Among Adults With Cancer and Atrial Fibrillation.
    Mehta HB; An H; Ardeshirrouhanifard S; Raji MA; Alexander GC; Segal JB
    Circ Cardiovasc Qual Outcomes; 2022 Dec; 15(12):e008951. PubMed ID: 36453260
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Concomitant Use of Diltiazem With Direct Oral Anticoagulants and Bleeding Risk in Atrial Fibrillation.
    Xu Y; Chang AR; Inker LA; McAdams-DeMarco M; Grams ME; Shin JI
    J Am Heart Assoc; 2022 Jul; 11(14):e025723. PubMed ID: 35861836
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of real-world clinical and economic outcomes in patients receiving oral anticoagulants: A retrospective claims analysis.
    Karnick C; Modany A; McGraw M; Ludwig J; Marr D; Hammonds T; Good CB; Culley E
    J Manag Care Spec Pharm; 2022 Nov; 28(11):1304-1315. PubMed ID: 36282935
    [No Abstract]   [Full Text] [Related]  

  • 30. A nationwide registry study to compare bleeding rates in patients with atrial fibrillation being prescribed oral anticoagulants.
    Halvorsen S; Ghanima W; Fride Tvete I; Hoxmark C; Falck P; Solli O; Jonasson C
    Eur Heart J Cardiovasc Pharmacother; 2017 Jan; 3(1):28-36. PubMed ID: 27680880
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Direct comparisons of effectiveness and safety of treatment with Apixaban, Dabigatran and Rivaroxaban in atrial fibrillation.
    Jansson M; Själander S; Sjögren V; Renlund H; Norrving B; Själander A
    Thromb Res; 2020 Jan; 185():135-141. PubMed ID: 31816553
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study.
    Nielsen PB; Skjøth F; Søgaard M; Kjældgaard JN; Lip GY; Larsen TB
    BMJ; 2017 Feb; 356():j510. PubMed ID: 28188243
    [No Abstract]   [Full Text] [Related]  

  • 33. Comparative effectiveness of warfarin, dabigatran, rivaroxaban and apixaban in non-valvular atrial fibrillation: A nationwide pharmacoepidemiological study.
    Kjerpeseth LJ; Selmer R; Ariansen I; Karlstad Ø; Ellekjær H; Skovlund E
    PLoS One; 2019; 14(8):e0221500. PubMed ID: 31449560
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Development and Validation of the DOAC Score: A Novel Bleeding Risk Prediction Tool for Patients With Atrial Fibrillation on Direct-Acting Oral Anticoagulants.
    Aggarwal R; Ruff CT; Virdone S; Perreault S; Kakkar AK; Palazzolo MG; Dorais M; Kayani G; Singer DE; Secemsky E; Piccini J; Tahir UA; Shen C; Yeh RW
    Circulation; 2023 Sep; 148(12):936-946. PubMed ID: 37621213
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Non-vitamin K antagonist oral anticoagulation agents in anticoagulant naïve atrial fibrillation patients: Danish nationwide descriptive data 2011-2013.
    Olesen JB; Sørensen R; Hansen ML; Lamberts M; Weeke P; Mikkelsen AP; Køber L; Gislason GH; Torp-Pedersen C; Fosbøl EL
    Europace; 2015 Feb; 17(2):187-93. PubMed ID: 25236181
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparative Effectiveness and Safety Between Apixaban, Dabigatran, Edoxaban, and Rivaroxaban Among Patients With Atrial Fibrillation : A Multinational Population-Based Cohort Study.
    Lau WCY; Torre CO; Man KKC; Stewart HM; Seager S; Van Zandt M; Reich C; Li J; Brewster J; Lip GYH; Hingorani AD; Wei L; Wong ICK
    Ann Intern Med; 2022 Nov; 175(11):1515-1524. PubMed ID: 36315950
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin in Frail Patients With Nonvalvular Atrial Fibrillation.
    Martinez BK; Sood NA; Bunz TJ; Coleman CI
    J Am Heart Assoc; 2018 Apr; 7(8):. PubMed ID: 29654196
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effectiveness and Safety of Direct Oral Anticoagulants in Thai Patients with Atrial Fibrillation: A Real-World Retrospective Cohort Study.
    Srikajornlarp S; Amnueypol M; Vathesatogkit P; Numthavaj P; Ungkanont A; Likittanasombat K; Pattanaprateep O; Angchaisuksiri P; Boonyawat K
    Clin Appl Thromb Hemost; 2022; 28():10760296221130058. PubMed ID: 36198021
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of major bleeding risk in patients with non-valvular atrial fibrillation receiving direct oral anticoagulants in the real-world setting: a network meta-analysis.
    Deitelzweig S; Farmer C; Luo X; Li X; Vo L; Mardekian J; Fahrbach K; Ashaye A
    Curr Med Res Opin; 2018 Mar; 34(3):487-498. PubMed ID: 29188721
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Gastrointestinal Safety of Direct Oral Anticoagulants: A Large Population-Based Study.
    Abraham NS; Noseworthy PA; Yao X; Sangaralingham LR; Shah ND
    Gastroenterology; 2017 Apr; 152(5):1014-1022.e1. PubMed ID: 28043907
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 47.